Indian pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) and the Russian Direct Investment Fund (RDIF) announced on Tuesday the launch of adaptive phase 2/3 clinical trials for the Sputnik V COVID-19 vaccine in India.
India's Central Drugs Laboratory has approved the multicentre and randomised controlled trial, which will include safety and immunogenicity study.
RDIF recently announced the second interim analysis of clinical trial data, which showed 91.4% efficacy for the vaccine on day 28 after the first dose and efficacy over 95% 42 days after the first dose.
Approximately 40,000 volunteers are currently taking part in Phase III clinical trials of Sputnik V, of whom over 22,000 have been vaccinated with the first dose of the vaccine and more than 19,000 with both the first and second doses.
Dr. Reddy's and RDIF entered into a partnership in September 2020 to conduct clinical trials of the Sputnik V vaccine and the rights for distribution of the first 100 million doses in India.
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial